BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9510141)

  • 1. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Nakano S; Kihara Y; Otsuki M
    Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Otsuki M; Nakano S; Tachibana I
    Regul Pept; 1994 Jul; 52(2):85-95. PubMed ID: 7972939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic oral administration of the CCK receptor antagonist loxiglumide on exocrine and endocrine pancreas in normal rats.
    Imoto I; Yamamoto M; Jia DM; Otsuki M
    Int J Pancreatol; 1997 Dec; 22(3):177-85. PubMed ID: 9444548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
    Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    Jia D; Yamamoto M; Otsuki M
    World J Gastroenterol; 2015 Jul; 21(25):7742-53. PubMed ID: 26167074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1994 Jul; 9(4):425-33. PubMed ID: 7937691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic fluid hypersecretion in rats after acute pancreatitis.
    Czakó L; Yamamoto M; Otsuki M
    Dig Dis Sci; 1997 Feb; 42(2):265-72. PubMed ID: 9052504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
    Shiratori K; Takeuchi T; Satake K; Matsuno S;
    Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of loxiglumide on pancreatic exocrine secretion stimulated by cholecystokinin-8 in conscious dogs.
    Ninomiya K; Saito T; Wakatsuki K; Saeki M; Kato T; Kasai H; Kimura K; Fujii M
    Arzneimittelforschung; 1998 Jan; 48(1):52-4. PubMed ID: 9522032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
    Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
    Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
    Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
    Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
    Satake K; Kimura K; Saito T
    Digestion; 1999; 60 Suppl 1():64-8. PubMed ID: 10026435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan.
    Ochi K; Harada H; Satake K
    Digestion; 1999; 60 Suppl 1():81-5. PubMed ID: 10026438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
    Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
    Tomita H; Miyasaka K; Jimi A; Mishima Y; Funakoshi A
    Pancreas; 1994 Sep; 9(5):638-45. PubMed ID: 7809019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
    Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
    Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasting prevents acute pancreatitis induced by cerulein in rats.
    Otsuki M; Tani S; Okabayashi Y; Fujii M; Nakamura T; Fujisawa T; Koide M; Itoh H
    Dig Dis Sci; 1990 Jul; 35(7):840-8. PubMed ID: 2364838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Tani S; Itoh H; Koide M; Okabayashi Y; Otsuki M
    Pancreas; 1993 Jan; 8(1):109-15. PubMed ID: 7678322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.